Suppr超能文献

依维莫司10毫克与胰腺神经内分泌肿瘤:不良反应众多且获益不明。

Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.

出版信息

Prescrire Int. 2012 Oct;21(131):234.

Abstract

In a placebo-controlled trial, the median time to radiologic documentation of cancer worsening or death was extended by about 6 months, although patients experienced many, often serious, adverse effects.

摘要

在一项安慰剂对照试验中,癌症恶化或死亡的放射学记录的中位时间延长了约6个月,尽管患者出现了许多往往较为严重的不良反应。

相似文献

2
Role of everolimus in pancreatic neuroendocrine tumors.
Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20.
3
Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4.
4
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8.
6
Everolimus for advanced pancreatic neuroendocrine tumors.
N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
7
Promising advances in the treatment of malignant pancreatic endocrine tumors.
N Engl J Med. 2011 Feb 10;364(6):564-5. doi: 10.1056/NEJMe1013903.
8
Recent studies show promise for treating rare pancreatic tumors.
J Natl Cancer Inst. 2011 Apr 20;103(8):624-7. doi: 10.1093/jnci/djr140. Epub 2011 Apr 7.
9
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.
Eur J Cancer. 2011 Oct;47(15):2249-55. doi: 10.1016/j.ejca.2011.03.017. Epub 2011 Apr 12.
10
Everolimus for the treatment of pancreatic neuroendocrine tumors.
Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Epub 2012 Aug 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验